Maintenance therapy with pemetrexed and bevacizumab versus pemetrexed monotherapy in non-squamous non-small-cell lung cancer.

Masato Karayama,Naoki Inui,Tomoyuki Fujisawa,Noriyuki Enomoto,Yutaro Nakamura,Shigeki Kuroishi,Koshi Yokomura,Naoki Koshimizu,Masaki Sato,Mikio Toyoshima,Toshihiro Shirai,Masafumi Masuda,Takashi Yamada,Shiro Imokawa,Takafumi Suda

Maintenance therapy with pemetrexed and bevacizumab versus pemetrexed monotherapy in non-squamous non-small-cell lung cancer.

2016

Masato Karayama
Naoki Inui
Tomoyuki Fujisawa
Noriyuki Enomoto
Yutaro Nakamura
Shigeki Kuroishi
Koshi Yokomura
Naoki Koshimizu
Masaki Sato
Mikio Toyoshima
Toshihiro Shirai
Masafumi Masuda
Takashi Yamada
Shiro Imokawa
Takafumi Suda

e20504Background: Maintenance therapy with pemetrexed is accepted as a standard therapy for advanced non-squamous non-small-cell lung cancer (NSCLC). Bevacizumab improves the efficacy of chemothera...

Keywords:

Bevacizumab
Pemetrexed
Pathology
Squamous non-small cell lung cancer
Oncology
Maintenance therapy
Medicine
Internal medicine
standard therapy
non small cell
Lung cancer
non squamous

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations